Last reviewed · How we verify
Biogeneric Epoetin
Biogeneric epoetin stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells, increasing red blood cell production.
Biogeneric epoetin stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells, increasing red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients undergoing major surgery.
At a glance
| Generic name | Biogeneric Epoetin |
|---|---|
| Sponsor | Ministry of Health, Malaysia |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Epoetin is a recombinant human erythropoietin that mimics the natural hormone responsible for regulating red blood cell production. It binds to erythropoietin receptors on erythroid progenitor cells in the bone marrow, triggering proliferation and differentiation into mature red blood cells. This mechanism is used therapeutically to treat anemia by restoring hemoglobin levels in patients with insufficient endogenous erythropoietin production.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in patients with cancer receiving chemotherapy
- Anemia in patients undergoing major surgery
Common side effects
- Hypertension
- Thromboembolism
- Headache
- Injection site reactions
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biogeneric Epoetin CI brief — competitive landscape report
- Biogeneric Epoetin updates RSS · CI watch RSS
- Ministry of Health, Malaysia portfolio CI